vs
Side-by-side financial comparison of Solana Co (HSDT) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $5.2M, roughly 1.7× Solana Co). Solana Co runs the higher net margin — 6227.1% vs -60.3%, a 6287.4% gap on every dollar of revenue. On growth, Solana Co posted the faster year-over-year revenue change (2725.9% vs -49.9%). Over the past eight quarters, Solana Co's revenue compounded faster (522.3% CAGR vs -6.7%).
Solana is a Mexican cottage manufacturer of sports, racing, and kids' automobiles based in Mexico City. The family run company has operated since 1936, with a total production of fewer than fifty cars; the majority of them one-offs. The family is heavily involved in motor sports; the most prominent member was Moisés Solana, who raced family-built cars and later in Formula One.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
HSDT vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.2M | $9.1M |
| Net Profit | $325.6M | $-5.5M |
| Gross Margin | 96.6% | 49.4% |
| Operating Margin | -3845.8% | -51.1% |
| Net Margin | 6227.1% | -60.3% |
| Revenue YoY | 2725.9% | -49.9% |
| Net Profit YoY | 8388.0% | -184.8% |
| EPS (diluted) | $111.28 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.2M | $9.1M | ||
| Q3 25 | $697.0K | $17.9M | ||
| Q2 25 | $43.0K | $15.7M | ||
| Q1 25 | $49.0K | $10.1M | ||
| Q4 24 | $185.0K | $18.2M | ||
| Q3 24 | $51.0K | $18.0M | ||
| Q2 24 | $182.0K | $13.5M | ||
| Q1 24 | $135.0K | — |
| Q4 25 | $325.6M | $-5.5M | ||
| Q3 25 | $-352.8M | $2.4M | ||
| Q2 25 | $-9.8M | $164.0K | ||
| Q1 25 | $-3.8M | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | $-3.7M | $3.2M | ||
| Q2 24 | $-1.6M | $-2.2M | ||
| Q1 24 | $-2.5M | — |
| Q4 25 | 96.6% | 49.4% | ||
| Q3 25 | 85.2% | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | 16.8% | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | 35.2% | 29.8% | ||
| Q1 24 | 8.9% | — |
| Q4 25 | -3845.8% | -51.1% | ||
| Q3 25 | -5086.1% | 11.9% | ||
| Q2 25 | -7725.6% | 7.5% | ||
| Q1 25 | -8185.7% | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | -7980.4% | 22.2% | ||
| Q2 24 | -1796.7% | -18.0% | ||
| Q1 24 | -2530.4% | — |
| Q4 25 | 6227.1% | -60.3% | ||
| Q3 25 | -50612.3% | 13.2% | ||
| Q2 25 | -22867.4% | 1.0% | ||
| Q1 25 | -7832.7% | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | -7227.5% | 18.0% | ||
| Q2 24 | -885.7% | -16.4% | ||
| Q1 24 | -1863.7% | — |
| Q4 25 | $111.28 | $-0.06 | ||
| Q3 25 | $-32.89 | $0.03 | ||
| Q2 25 | $-79.73 | $0.00 | ||
| Q1 25 | $-0.51 | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | $-744.35 | $0.03 | ||
| Q2 24 | $-485.30 | $-0.03 | ||
| Q1 24 | $-3.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.3M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $300.9M | $48.2M |
| Total Assets | $303.9M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.3M | $14.7M | ||
| Q3 25 | $124.1M | $13.6M | ||
| Q2 25 | $6.1M | $17.9M | ||
| Q1 25 | $1.1M | $19.5M | ||
| Q4 24 | $1.1M | $19.8M | ||
| Q3 24 | $3.5M | $27.4M | ||
| Q2 24 | $6.4M | $23.4M | ||
| Q1 24 | $3.6M | — |
| Q4 25 | $300.9M | $48.2M | ||
| Q3 25 | $-152.4M | $52.9M | ||
| Q2 25 | $6.0M | $49.9M | ||
| Q1 25 | $1.3M | $45.2M | ||
| Q4 24 | $1.1M | $43.2M | ||
| Q3 24 | $3.8M | $32.4M | ||
| Q2 24 | $6.3M | $28.6M | ||
| Q1 24 | $2.0M | — |
| Q4 25 | $303.9M | $82.3M | ||
| Q3 25 | $475.9M | $82.3M | ||
| Q2 25 | $7.9M | $78.5M | ||
| Q1 25 | $3.5M | $73.9M | ||
| Q4 24 | $3.5M | $73.4M | ||
| Q3 24 | $5.6M | $61.6M | ||
| Q2 24 | $8.8M | $91.5M | ||
| Q1 24 | $5.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.5M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | -0.05× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-16.5M | $2.0M | ||
| Q3 25 | $-4.0M | $-3.7M | ||
| Q2 25 | $-2.8M | $-5.2M | ||
| Q1 25 | $-3.5M | $-5.1M | ||
| Q4 24 | $-11.0M | $4.0M | ||
| Q3 24 | $-2.8M | $4.1M | ||
| Q2 24 | $-2.9M | $-3.6M | ||
| Q1 24 | $-3.0M | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | $-11.0M | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | $-3.0M | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | -5970.8% | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | -2226.7% | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | 2.7% | 2.3% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | 0.0% | 1.3% | ||
| Q1 24 | 3.7% | — |
| Q4 25 | -0.05× | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HSDT
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
